1. Scrip
  2. >>Focus On Asia
  3. >>China

Can BlissBio’s HER2-Targeting ADC Challenge Enhertu In Breast Cancer?

Eisai Deal Sets Stage For Battle

 
• By Dexter Jie Yan

A new deal worth up to $2bn-plus with Eisai has put Bliss Biopharmaceutical's HER2-targeting antibody-drug conjugate BB-1701 in the spotlight, as the global race heats up to find a possible challenger to Enhertu.

challenger facing hurdles
Any serious challenger to Enhertu will face hurdles, especially in breast cancer • Source: Shutterstock

Japanese major Eisai Co., Ltd.’s option deal worth up to $2bn-plus for the in-licensing of a HER2-targeting antibody-drug conjugate (ADC) developed by Chinese biotech Bliss Biopharmaceutical (BlissBio), showed just how intensively international pharma firms are scouting China-originated assets for a potential challenger to Daiichi Sankyo Co., Ltd./AstraZeneca PLC's Enhertu (trastuzumab deruxtecan) for breast cancer.

Eisai and BlissBio announced on 8 May a clinical trial collaboration agreement with an option for a strategic collaboration for...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

More from Focus On Asia

Sino Biopharm Scoops LaNova In Chinese Pharma’s Biggest Biotech Buyout So Far

 
• By Dexter Jie Yan

Sino Biopharm will pay almost $1bn to acquire what target LaNova’s CEO described as an “exploding” pipeline, which includes six clinical-stage candidates in the oncology area.

China Sentences Astellas Employee To 3.5 Years In Prison On Spy Charges

 
• By Lisa Takagi

An employee of Astellas faces three and a half years in prison after sentencing by a court in China on espionage charges.

Sun’s Alopecia Treatment Debuts In US - Can It Make Up For Lost Time?

 
• By Anju Ghangurde

Sun’s Leqselvi goes up against Lilly's Olumiant and Pfizer's Litfulo, which currently has the broadest label, in the US alopecia market. Can it shake things up early, amid growing activity in the space with several new mechanisms of action being investigated?